Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Loos

Showing results (141-150 of 215) with videos related to

Pageof 22
Sort By:
European Journal of Cancer (Oxford, England : 1990)|December 26, 2001
Modulation of cisplatin pharmacodynamics by Cremophor EL: experimental and clinical studiesH Gelderblom, W J Loos, J Verweij, et al.
European Journal of Cancer (Oxford, England : 1990)|March 11, 2004
Real-time pharmacokinetics guiding clinical decisions; phase I study of a weekly schedule of liposome encapsulated paclitaxel in patients with solid tumoursO Soepenberg, A Sparreboom, M J A de Jonge, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 23, 2004
A phase I pharmacokinetic and pharmacodynamic study of the farnesyl transferase inhibitor BMS-214662 in combination with cisplatin in patients with advanced solid tumorsHelen J Mackay, Ronald Hoekstra, Ferry A L M Eskens, et al.
Anti-Cancer Drugs|June 23, 1999
Phase I and pharmacologic study of the arotinoid Ro 40-8757 in combination with cisplatin and etoposide in patients with non-small cell lung cancerL van Zuylen, J H Schellens, S H Goey, et al.
Cancer Chemotherapy and Pharmacology|January 22, 2008
Continuous ambulatory peritoneal dialysis: pharmacokinetics and clinical outcome of paclitaxel and carboplatin treatmentJoan B Heijns, Maria E L van der Burg, Teun van Gelder, et al.
British Journal of Cancer|November 17, 2001
Dose and schedule-finding study of oral topotecan and weekly cisplatin in patients with recurrent ovarian cancerH Gelderblom, A Sparreboom, M J de Jonge, et al.
Journal of Pharmaceutical and Biomedical Analysis|November 15, 2011
Quantification of cabazitaxel in human plasma by liquid chromatography/triple-quadrupole mass spectrometry: a practical solution for non-specific bindingPeter de Bruijn, Anne-Joy M de Graan, Annemieke Nieuweboer, et al.
Anti-Cancer Drugs|April 9, 1999
Sparse-data set analysis for irinotecan and SN-38 pharmacokinetics in cancer patients co-treated with cisplatinR H Mathijssen, R J van Alphen, M J de Jonge, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 22, 2005
Association of CYP2C8, CYP3A4, CYP3A5, and ABCB1 polymorphisms with the pharmacokinetics of paclitaxelAnja Henningsson, Sharon Marsh, Walter J Loos, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1996
Docetaxel and paclitaxel inhibit DNA-adduct formation and intracellular accumulation of cisplatin in human leukocytesJ Ma, J Verweij, A S Planting, et al.
Pageof 22

Showing results (141-150 of 215) with videos related to

Sort By:
Pageof 22
European Journal of Cancer (Oxford, England : 1990)|December 26, 2001
Modulation of cisplatin pharmacodynamics by Cremophor EL: experimental and clinical studiesH Gelderblom, W J Loos, J Verweij, et al.
European Journal of Cancer (Oxford, England : 1990)|March 11, 2004
Real-time pharmacokinetics guiding clinical decisions; phase I study of a weekly schedule of liposome encapsulated paclitaxel in patients with solid tumoursO Soepenberg, A Sparreboom, M J A de Jonge, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 23, 2004
A phase I pharmacokinetic and pharmacodynamic study of the farnesyl transferase inhibitor BMS-214662 in combination with cisplatin in patients with advanced solid tumorsHelen J Mackay, Ronald Hoekstra, Ferry A L M Eskens, et al.
Anti-Cancer Drugs|June 23, 1999
Phase I and pharmacologic study of the arotinoid Ro 40-8757 in combination with cisplatin and etoposide in patients with non-small cell lung cancerL van Zuylen, J H Schellens, S H Goey, et al.
Cancer Chemotherapy and Pharmacology|January 22, 2008
Continuous ambulatory peritoneal dialysis: pharmacokinetics and clinical outcome of paclitaxel and carboplatin treatmentJoan B Heijns, Maria E L van der Burg, Teun van Gelder, et al.
British Journal of Cancer|November 17, 2001
Dose and schedule-finding study of oral topotecan and weekly cisplatin in patients with recurrent ovarian cancerH Gelderblom, A Sparreboom, M J de Jonge, et al.
Journal of Pharmaceutical and Biomedical Analysis|November 15, 2011
Quantification of cabazitaxel in human plasma by liquid chromatography/triple-quadrupole mass spectrometry: a practical solution for non-specific bindingPeter de Bruijn, Anne-Joy M de Graan, Annemieke Nieuweboer, et al.
Anti-Cancer Drugs|April 9, 1999
Sparse-data set analysis for irinotecan and SN-38 pharmacokinetics in cancer patients co-treated with cisplatinR H Mathijssen, R J van Alphen, M J de Jonge, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 22, 2005
Association of CYP2C8, CYP3A4, CYP3A5, and ABCB1 polymorphisms with the pharmacokinetics of paclitaxelAnja Henningsson, Sharon Marsh, Walter J Loos, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1996
Docetaxel and paclitaxel inhibit DNA-adduct formation and intracellular accumulation of cisplatin in human leukocytesJ Ma, J Verweij, A S Planting, et al.
Pageof 22